Advanced and oligoprogressive NSCLC
Oncology Institute of Southern Switzerland
II
2de line
Atezolizumab plus 8 Gy single-fraction radiotherapy
Asymptomatic central nervous system (CNS) metastases are eligible
HUG
To evaluate preliminary efficacy, safety and tolerability of atezolizumab in combination with palliative radiotherapy in adult patients diagnosed with advanced NSCLC, irrespective of PD-L1 status, and who have oligoprogressed to both immunotherapy with anti-PD-1 and one line of chemotherapy